R. Dubowy

发表

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

A. Zelenetz, I. Flinn, T. Kipps, 2015, Blood.

Role of carbonate in the cytotoxicity of carboplatin.

D. Kerwood, A. D. Di Pasqua, J. Goodisman, 2007, Chemical research in toxicology.

Activation of carboplatin by carbonate.

D. Kerwood, A. D. Di Pasqua, J. Goodisman, 2006, Chemical research in toxicology.

Zinc-induced copper deficiency in an infant.

M. Oliphant, A. Botash, R. Dubowy, 1992, American journal of diseases of children.

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

A. Kraft, M. Bernstein, R. Berkow, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium study

P. Adamson, A. Souid, S. Blaney, 2010, Pediatric blood & cancer.

Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.

M. Link, M. Devidas, M. Gebhardt, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.

P. Riedell, L. Gordon, A. D’Andrea, 2022, The Lancet. Oncology.

Modification and Uptake of a Cisplatin Carbonato Complex by Jurkat Cells

D. Kerwood, J. Goodisman, J. Dabrowiak, 2006, Molecular Pharmacology.

Excretion of hydroxyurea into milk

M. Lobell, R. Dubowy, R. Sylvester, 1987, Cancer.

Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue.

C. Civin, P. Colombani, M. Wharam, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials

Jeffrey A Jones, A. Zelenetz, M. Hallek, 2018, Leukemia & lymphoma.

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Jeffrey A Jones, I. Flinn, F. Awan, 2017, The Lancet. Haematology.

Endothelial cell proliferation may be mediated via the production of endogenous lipoxygenase metabolites.

B. Setty, M. Stuart, R. Dubowy, 1987, Biochemical and biophysical research communications.

Inhibition of human malignant neuroblastoma cell DNA synthesis by lipoxygenase metabolites of arachidonic acid.

M. Stuart, R. Walenga, S. Boone, 1985, Cancer research.

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

R. Mesa, D. Mclornan, J. Gotlib, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.

W. McLeod, M. Bernstein, A. Souid, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors 1

W. McLeod, M. Bernstein, A. Souid, 2003 .

Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.

M. Bernstein, G. Newton, R. C. Fahey, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts.

Matthew J. Oborski, F. Toledo, J. Mountz, 2012 .

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

J. Mountz, A. Tolcher, M. Lotze, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of mean cell volume in non‐Hodgkin's lymphomas

F. Davey, J. Goldberg, R. Dubowy, 1986, Cancer.

A phase 2 study of idelalisib plus rituximab in treatment-na¨ ı ve older patients with chronic lymphocytic leukemia

A. Zelenetz, I. Flinn, M. Keating, 2015 .

Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer.

D. V. Von Hoff, G. Weiss, M. Jeffers, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.

R. Krance, A. Carroll, J. Pullen, 1992, Leukemia.

Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis.

F. Bosch, M. Westerhoff, D. Hockenbery, 2018, Future oncology.

Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs.

Jerry Goodisman, Mehmet K Aktas, Abdul-Kader Souid, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Sequential Oral Hydroxyurea and Intravenous Cytosine Arabinoside in Refractory Childhood Acute Leukemia: A Pediatric Oncology Group Phase 1 Study

Y. Ravindranath, B. Camitta, D. Mahoney, 2008, Journal of pediatric hematology/oncology.

Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol®) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography

M. Bernstein, G. Newton, R. C. Fahey, 1998, Cancer Chemotherapy and Pharmacology.

A phase I trial of fazarabine in refractory pediatric solid tumors

M. Bernstein, F. Kung, H. Grier, 1993, Investigational New Drugs.

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab

A. Pettitt, M. Hallek, S. Stilgenbauer, 2019, Leukemia.

Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493).

L. Frankel, J. Shuster, M. Borowitz, 1997, Journal of pediatric hematology/oncology.

Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia

F. Davey, D. Barrett, R. Dubowy, 1991, Cancer.

Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.

M. Bernstein, C. Pratt, H. Grier, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Teaching Teachers About Childhood Cancer: The Effects of a Web-based Training Program

Ava E. Kleinmann, B. Rieger, L. Lewandowski, 2006, Journal of pediatric hematology/oncology.

Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A. Zelenetz, I. Flinn, T. Kipps, 2014 .

Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.

J. Krischer, Y. Ravindranath, E. Abella, 1992, Blood.

Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience

Douglas C. Miller, M. Rosenblum, J. Finlay, 2008, Pediatric blood & cancer.

Controversy in the management of optic nerve glioma

G. A. King, R. Sagerman, C. Chung, 1986, Cancer.

Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study.

R. Parmley, B. Pollock, C. Pratt, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Demyelinating and gliotic cerebellar lesions in Langerhans cell histiocytosis.

C. Hodge, G. H. Collins, C. Crosley, 1994, AJNR. American journal of neuroradiology.

Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue

Douglas C. Miller, M. Rosenblum, J. Finlay, 2007, Pediatric blood & cancer.

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Jeremiah D. Degenhardt, R. Rosenquist, S. Stilgenbauer, 2016 .

Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

A. Zelenetz, S. O'brien, Jennifer R. Brown, 2017, Leukemia.

A Phase 2 Study of Idelalisib Monotherapy in Previously Untreated Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A. Zelenetz, I. Flinn, T. Kipps, 2014 .

Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

J. Leonard, I. Flinn, S. Coutre, 2013 .

Pathology Results of Tissue Biopsy during Idelalisib-Associated Diarrhea/Colitis

F. Bosch, M. Westerhoff, D. Hockenbery, 2016 .

A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

A. Zelenetz, I. Flinn, T. Kipps, 2013 .

Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).

Jeffrey A Jones, I. Flinn, Jennifer R. Brown, 2015 .

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

D. V. Von Hoff, G. Weiss, M. Jeffers, 2013, Clinical Cancer Research.

Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study.

A. Pappo, Y. Ravindranath, T. Vietti, 1990, Journal of the National Cancer Institute.

RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Jeffrey A Jones, F. Bosch, P. Feugier, 2015 .

A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation

J. Holland, F. Kung, A. Kornblith, 1998, Cancer.

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jeffrey A Jones, J. Byrd, A. Zelenetz, 2017 .

WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study

M. Bernstein, G. Newton, R. C. Fahey, 1999, Cancer Chemotherapy and Pharmacology.

Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors

J. Krischer, F. Kung, G. Brodeur, 1988, Investigational New Drugs.

No responses to oral etoposide in 15 patients with recurrent brain tumors.

D. Korones, P. Fisher, K. Cohen, 2000, Medical and Pediatric Oncology.

Pediatric cerebellar pleomorphic xanthoastrocytoma with anaplastic features: a case of long-term survival after multimodality therapy

J. Latorre, Howard T. Chang, R. Schelper, 2006, Child's Nervous System.

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

A. Zelenetz, J. Leonard, I. Flinn, 2013 .

The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors

J. Katz, G. Rivard, B. Kroner, 2002, Thrombosis and Haemostasis.

A Phase I study of acivicin in refractory pediatric solid tumors

S. Baruchel, M. Bernstein, H. Grier, 2004, Investigational New Drugs.

Phase II Trial of Pyrazoloacridine in Children With Solid Tumors: A Pediatric Oncology Group Phase II Study

M. Bernstein, M. Harris, S. Berg, 2000, Journal of pediatric hematology/oncology.

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.

A. Zelenetz, I. Flinn, T. Kipps, 2015, Blood.